卡马替尼对地高辛和瑞舒伐他汀药代动力学的影响:一项I期药物相互作用研究
该研究在MET异常晚期实体瘤患者中评估卡马替尼对P-gp底物地高辛和BCRP底物瑞舒伐他汀药代动力学的影响。结果显示卡马替尼使地高辛AUC和Cmax分别增至1.47倍和1.74倍,使瑞舒伐他汀AUC和Cmax分别增至2.08倍和3.04倍。研究表明卡马替尼是P-gp和BCRP抑制剂,具有临床相关药物相互作用潜力。
要点
- 卡马替尼使地高辛AUC增至1.47倍、Cmax增至1.74倍,提示P-gp抑制作用。
- 卡马替尼使瑞舒伐他汀AUC增至2.08倍、Cmax增至3.04倍,提示BCRP抑制作用。
- 联合使用P-gp或BCRP底物药物时需警惕药物相互作用风险。
核心结论
- 卡马替尼是P-gp和BCRP转运体抑制剂,具有临床相关药物相互作用潜力。
研究设计与样本
- 多中心、开放标签、单序列I期药物相互作用研究,纳入32例MET异常晚期实体瘤成人患者。
- 第1天给予含0.25 mg地高辛和10 mg瑞舒伐他汀的口服药物鸡尾酒,第22天联合卡马替尼重复给药。
- 第11至32天卡马替尼400 mg每日两次给药以达到稳态进行药物相互作用评估。
主要发现
- 地高辛联合卡马替尼vs单用:AUCinf几何均值比1.47(90%CI 1.28,1.68),Cmax几何均值比1.74(90%CI 1.43,2.13)。
- 瑞舒伐他汀联合卡马替尼vs单用:AUCinf几何均值比2.08(90%CI 1.56,2.76),Cmax几何均值比3.04(90%CI 2.36,3.92)。
- 所有级别最常见不良事件(≥25%)为恶心、乏力、便秘、呕吐、外周水肿和发热。
- 3/4级最常见不良事件(≥5%)为贫血、肺栓塞、乏力、呼吸困难、恶心和呕吐。
关键数值与推荐
- 地高辛0.25 mg单次口服与卡马替尼400 mg每日两次联用。
- 瑞舒伐他汀10 mg单次口服与卡马替尼400 mg每日两次联用。
临床怎么用
- 卡马替尼治疗期间联用P-gp底物(如地高辛)或BCRP底物(如瑞舒伐他汀)需考虑剂量调整或监测。
局限性
- 研究为单序列设计,未设平行对照。
- 样本量有限(32例),纳入MET异常晚期实体瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic nonsmall cell lung cancer with METex14 skipping mutations. The study investigated the effect of capmatinib on the pharmacokinetics of a single oral dose of digoxin and rosuvastatin in patients with MET-dysregulated advanced solid tumours. METHODS: This was a multicentre, open-label, single-sequence study. An oral drug cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin was administered to adult patients with MET-dysregulated advanced solid tumours on Day 1, and then on Day 22 with capmatinib. Between Days 11 and 32, capmatinib 400 mg was administered twice daily to ensure the attainment of steady state for drug-drug interaction assessment. Pharmacokinetics of cocktail drugs and safety of capmatinib were evaluated. RESULTS: Thirty-two patients were enrolled. Compared to digoxin alone, the geometric mean ratios (90% confidence interval) of area under the concentration-time curve from time zero to infinity and maximum concentration for digoxin plus capmatinib were 1.47 (1.28, 1.68) and 1.74 (1.43, 2.13), respectively. Compared to rosuvastatin alone, the geometric mean ratios (90% confidence interval) of area under the curve to infinity and maximum concentration for rosuvastatin plus capmatinib were 2.08 (1.56, 2.76) and 3.04 (2.36, 3.92), respectively. Most frequent adverse events (≥25% for all grades) were nausea, asthenia, constipation, vomiting, peripheral oedema and pyrexia. Most frequent Grade 3/4 adverse events (≥5%) were anaemia, pulmonary embolism, asthenia, dyspnoea, nausea and vomiting. CONCLUSION: This study demonstrated that capmatinib is an inhibitor of P-gp and BCRP transporters, with clinically relevant drug-drug interaction potential. Capmatinib was well-tolerated and no unexpected safety concerns were observed.
引用
- Grande E, Giovannini M, Marriere E, et al. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol. 2020. PMID: 33300203. doi:10.1111/bcp.14697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。